PACTR202403493915530尚未招募2 期
A Seamless Phase 2B/2C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary Tuberculosis
niversity College London0 个研究点目标入组 2,500 人开始时间: 2024年2月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 2,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •1.Age 18 years or above at screening (or above age of legal consent at screening, if this is higher than 18 years in the jurisdiction in which the study is taking place)
- •2.Clinical evidence of active TB disease, meeting either or both of the following criteria:
- •Symptoms consistent with pulmonary TB at screening AND/OR
- •Imaging findings consistent with active pulmonary TB on chest X-ray performed at screening or within 7 days prior to screening
- •3.At least one sputum specimen produced at screening tested on Xpert MTB/RIF Ultra that has:
- •a semi-quantitative result of ‘medium' or 'high' AND
- •does not show rifampicin resistance
- •4.Body weight within the range of 30 to 100kg and body mass index within the range of 15 to 40kg/m2
- •5.Willing to comply with study visits, all study procedures and treatment observation
- •6.Resident at a fixed address that is readily accessible for visiting, within feasible travelling distance to the site and likely to remain resident there for the duration of trial follow-up
- •7.Has provided written informed consent
排除标准
- •1.Taken more than 1 daily dose of medication with anti-tuberculous activity during the 14 days prior to randomisation (isoniazid, rifampicin, pyrazinamide, ethambutol; linezolid, moxifloxacin, levofloxacin or amikacin)*
- •2.Known isoniazid resistance (at sites where national isoniazid monoresistance is greater than 10% rapid testing at screening is mandated; at other sites rapid testing at screening is optional)
- •3.Known or suspected extra-thoracic TB, miliary TB or disseminated TB (in the judgement of the investigator; note uncomplicated pleural effusion occupying <50% of hemithorax or concomitant intra- or extra-thoracic lymphadenopathy are not exclusions)
- •4.Severe clinical pulmonary TB e.g. respiratory failure or complications likely to require hospital admission in the opinion of the investigator
- •5.Poor general condition (Karnofsky score =50) OR where any delay in treatment cannot be tolerated in the opinion of the investigator
- •6.Active malignancy requiring systemic therapy, radiotherapy or palliative therapy
- •7.History of myocardial infarction, coronary heart disease or congestive cardiac failure; long QT syndrome or clinically significant arrhythmias; pulmonary hypertension; any known congenital cardiac problems; family history of long QT syndrome or sudden death from unknown or cardiac related cause; uncontrolled arterial hypertension (not excluded if this is corrected prior to randomisation)
- •8.Vitiligo
- •9.History of seizure(s)
- •10.Current tendinitis (any cause) or history of tendinopathy associated with fluoroquinolone use
- •11.History of vascular aneurysm
- •12.Symptomatic peripheral neuropathy causing greater than minimal interference with usual social and functional activities
- •13.Current alcohol or illicit drug use sufficient to compromise the safety of the participant or research staff or compromise adherence to study procedures, in the opinion of the investigator
- •14.Any current or recent use of amphetamines or methamphetamines, either reported or e
研究者
相似试验
招募中
1 期
Study with Various Immunotherapy Treatments in Participants With Lung CancerAdvanced Non-Small Cell Lung CancerCTIS2022-502916-35-01Arcus Biosciences Inc.263
进行中（未招募）
1 期
A Phase II Study of Novel Regimens Versus Standard of Care Treatment in Non-Small Cell Lung Cancernon-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001316-29-NLGlaxoSmithKline Research and Development Ltd.105
进行中（未招募）
1 期
A Phase II Study of Novel Regimens Versus Standard of Care Treatment in Non-Small Cell Lung Cancernon-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001316-29-DKGlaxoSmithKline Research and Development Ltd.105
进行中（未招募）
1 期
A Phase II Study of Novel Regimens Versus Standard of Care Treatment in Non-Small Cell Lung Cancernon-small cell lung cancer (NSCLC)MedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001316-29-FRGlaxoSmithKline Research and Development Ltd.105
进行中（未招募）
1 期
A Phase II Study of Novel Regimens Versus Standard of Care Treatment in Non-Small Cell Lung Canceron-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001316-29-SEGlaxoSmithKline Research and Development Ltd.341